The oncogenic tyrosine kinase Src has a role in cancer development, especially by promoting invasive and metastatic behavior. It is, however, unclear which of the Srcregulated signaling cascades induce malignant phenotype in three-dimensional environment. One of Src substrates is ezrin, a cytoskeletal organiser and regulator of signal transduction. Ezrin expression correlates with poor outcome of diverse cancers and is essential in experimental metastatic osteosarcoma. We reconstituted genetically ezrin-deficient cells with wild-type (WT) or phosphorylation-deficient Y477F ezrin together with constitutively active Src. In two-dimensional cultures, Src induced malignant features regardless of the presence or absence of ezrin. In contrast, only WT ezrin-expressing cells grew efficiently in soft agar or in suspension. In Matrigel, only WT ezrin significantly promoted growth and invasion, and was targeted to specific regions on the plasma membrane. WT and Y477F ezrin-expressing cells showed marked differences only when growing or scattering in threedimensional matrix. Additional experiments showed that Y477-phosphorylated ezrin is also needed for the growth of Src-transformed epithelial cells in three-dimensional matrix. Cells lacking functional ezrin had reduced cyclin D levels and fewer cells in G2 þ S phase, possibly as a consequence of abnormal mTOR signaling, as ezrin Y477F cells showed lower expression of phosphorylated intermediates downstream of mTOR than WT cells. We conclude that the pathways activated by Src depend on the type of environment and that ezrin is a crucial element of Src-induced malignant features in cells growing inside three-dimensional environment.
Introduction
The non-receptor tyrosine kinase Src is the first identified proto-oncogene (reviewed in Martin, 2001) . Src regulates a variety of cellular functions and signaling pathways, for example, cell survival, migration and invasion. Increased expression or activation of Src has been shown in many types of human primary cancers, especially in metastastic tumors (Irby and Yeatman, 2000; Frame, 2002) . In human colorectal carcinoma, Src activity is an independent indicator of poor clinical prognosis in all stages of cancer dissemination (Aligayer et al., 2002) , but increased Src levels and activating mutations are detected as colon tumors progress (Talamonti et al., 1993; Cartwright et al., 1994; Mao et al., 1997; Irby et al., 1999) . Increased Src activity is not thought to be essential for early tumorigenic events of human tumors. Rather, Src seems to provide a selective advantage to tumor cells during metastatic processes by facilitating invasion and spreading to distant organs. Src inhibitors are extensively investigated for cancer therapy (Jones et al., 2002; Boyd et al., 2004) .
One of Src substrates is ezrin, an ERM (ezrin-radixinmoesin) family protein that connects cell membrane and actin cytoskeleton (reviewed in Bretscher et al., 2002) . Ezrin is implicated in signal transduction networks both as a regulator and an effector interacting with various members of protein kinase A, Rho and phosphatidylinositol-3 kinase signaling pathways. Ezrin is the only ERM protein shown to be directly phosphorylated on tyrosine by the Src family kinases Lck and Src (Autero et al., 2003; Heiska and Carpen, 2005; Srivastava et al., 2005) . The Src-induced phosphorylation on tyrosine Y477 leads to binding of a Kelch-repeat family protein KBTBD2 (Kelch-repeat and BTB/POZ domain binding 2) and Fes kinase, a member of fes/fps non-receptor protein kinase subfamily (Heiska and Carpen, 2005; Naba et al., 2008) . Src and ezrin function cooperatively in deregulation of cell-cell contacts and scattering of carcinoma cells (Elliott et al., 2004) . However, the cellular effects of Src-dependent ezrin phosphorylation are largely unknown.
Ezrin has been implicated in human tumorigenesis, especially metastatic processes in tumors of both epithelial and non-epithelial origin. Upregulation of ezrin correlates with invasive characteristics of malignant cell lines, as well as with malignancy, metastatic behavior and poor clinical outcome of diverse cancers (Geiger et al., 2000; Makitie et al., 2001; Ohtani et al., 2002; Ilmonen et al., 2005; Weng et al., 2005; Kobel et al., 2006; Bruce et al., 2007; Elzagheid et al., 2008) . By a microarray approach, Khanna et al. (2004) identified ezrin as an essential protein for experimental metastatic osteosarcoma and a marker of poor outcome in spontaneous canine osteosarcomas and in pediatric osteosarcomas. The ezrin-dependent activity was later linked to the mammalian target of rapamycin (mTOR)-eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) pathway downstream of Akt (Wan et al., 2005) . Furthermore, microarray-based profiling of highly and poorly metastatic rhabdomyosarcoma lines and a subsequent analysis of the human patient samples showed that ezrin expression is a key prometastatic regulator (Yu et al., 2006) .
As increased ezrin expression and Src activity correlate with malignant behavior in vivo, and as ezrin is a substrate for Src, we investigated whether ezrin and Src function in concert in induction of oncogenic characteristics. We used genetically engineered ezrindeficient mouse embryonic fibroblasts (MEFs) and reintroduced them with wild-type (WT) ezrin or phosphorylation-deficient ezrin in combination with constitutively active Src. Our results show that ezrin is a major regulator of Src-induced anchorage-independent growth and cell invasion. In contrast, ezrin mutant that cannot be phosphorylated by Src, does not promote these activities. Moreover, the requirement of ezrin phosphorylation for malignant behavior is only evident in cells growing in three-dimensional environment. The results were further reproduced in a Src-transformed rat epithelial cell line suggesting that the Src-ezrin interplay is effective in wider cellular context and could contribute Src-induced malignant features.
Results

Characterization of mouse embryonic fibroblasts subclones
We used MEF cells from the ezrin knockout mouse to study the role of ezrin in Src-induced cellular functions. We and others have mapped the target residues of Src family kinases in ezrin to Y145 and Y477 (Autero et al., 2003; Heiska and Carpen, 2005; Srivastava et al., 2005) . Thus, the ezrin À/À MEF cells were stably introduced with the WT, the Y145F mutant, the Y477F mutant ezrin expression constructs or with the plasmid vector alone. Ezrin expression in add-back cells was verified by immunoblotting ( Figure 1a ). The absence of ezrin appeared not to be compensated by expressional or functional upregulation of other ERM proteins, as moesin expression and its threonine 558 phosphorylation was equal in the parent MEFs and the subclones (Figures 1b and c) . Therefore we concluded that the MEFs subclones were appropriate for studies on the role of Src-induced phosphorylation.
The cells were further introduced with a constitutively active Src (Y527F) expression construct. Src activity was controlled by immunoblotting of the cell lysates with an anti-(pY418) Src antibody, which recognizes Src only when its autoactivating Y418 residue is phosphorylated (Figure 1d ). The cells expressing Y527F Src showed prominent overall tyrosine phosphorylation compared with the cells which were not expressing active Src, as detected with an anti-(pY) antibody (data not shown). Introduction of active Src construct led to the upregulation of ezrin in the MEFs add-back clones (compare lane 2 in Figure 1a with lanes 4-6), in line with a previous fingerprint analysis of Src-regulated changes in gene expression (Malek et al., 2002) .
Ezrin from the various subclones was immunoprecipitated to study whether ezrin serves as a Src substrate in this model and to analyze the targeted tyrosine. In the presence of Src, both the WT and the Y145F mutant ezrin were phosphorylated on tyrosine, whereas mutation of Y477 abolished the reactivity almost completely. The results verify that ezrin is a substrate for Srcinduced tyrosine phosphorylation and Y477 is the main target in the MEFs subclones. Therefore, in the following experiments the cells expressing empty vector, WT ezrin or the Y477F mutant ezrin were included.
Ezrin is not required for Src-induced alterations in cells grown on two-dimensional surfaces Next, we examined the localization of ezrin in the different sublones grown on coverslips. In the ezrin À/À MEFs add-back cells, both WT (Figure 2a ) and Y477F ezrin (not shown) were localized to short extensions at the cell membrane. The vector control cells were not recognized with the anti-ezrin antibody (Figure 2d ). Active Src changed the cellular morphology from the normal fibroblast like to a more polygonal and refracted appearance characteristic for transformed cells. No differences were seen between the localization of the WT and the mutant form of ezrin. Both forms were partly concentrated to the plasma membrane and partly located diffusely in the cytoplasm (Figures 2b and c) . Brightly stained spots of ezrin were seen at cellular protrusions or active membrane areas. Expression of active Src prominently altered actin cytoskeleton. The pronounced stress fibers ( Figure 2e) were disappeared, and F-actin was heavily concentrated in podosomal or rosette-like structures regardless of the ezrin protein status (Figure 2f ; not all subclones are shown). The active Src was located exclusively in the podosome-like structures (Figure 2g ). However, the localization was similar in the subclone containing the Y477F mutant ezrin (Figure 2h ). The podosomal structures further contained cortactin, a well-known Src substrate (not shown). In ezrin-expressing subclones, these structures occasionally contained ezrin, whether mutant or WT (data not shown). The results confirm earlier studies on the effects of Src kinase activity on cell morphology and cytoskeleton and show that ezrin is not required for podosome formation in MEFs. Furthermore, the results indicate that the role of ezrin Y477 phosphorylation by Src is not involved in the targeting of either ezrin or Src in two-dimensional cell cultures.
To further address the role of ezrin Y477 phosphorylation, we used standard assays for functions implicated in Src activation. First, we measured the proliferation capacity of the different subclones grown on cell culture plates (Figure 3a) . The absence or presence of WT or mutated ezrin did not affect the adhesion-dependent growth of the clones on a culture plate. However, the presence of active Src clearly enhanced the proliferation of all clones compared with the parental clones (only parental clone expressing WT ezrin is shown).
Next, we studied the effects on cell adhesion. No ezrin-dependent differences in attachment or in the kinetics of adherence were seen by microscopic examination. This was further verified by quantitative measurements. The presence of active Src similarly increased the rate of adherence of all subclones ( Figure 3b ). In the classical wound healing experiment, the subclones containing the different ezrin constructs or the plasmid control did not show any differences in migration (data not shown). The cells containing constitutively active Src were highly motile and easily detached from the substrate in the wound-healing assay.
Y477 phosphorylation-proficient ezrin is required for Srcinduced malignant behavior of cells in three-dimensional matrix In earlier studies, ezrin has been implicated in migration of cancer cells in three-dimensional matrices or in tubulogenesis of kidney cells in collagen matrix (Gautreau et al., 1999; Sahai and Marshall, 2003) . We set up assays involving three-dimensional matrices in order to evaluate possible differences between the subclones and the significance of the Src-induced phosphorylation. In WT ezrin cells seeded in Matrigel (Figure 4a ), ezrin was heavily polarized, concentrating in submembraneous clusters or patches. Instead, the Y477F mutant ezrin was located diffusely in the cytoplasm and did not concentrate to the surface or localize to cell extensions ( Figure 4b ). Also active Src was highly concentrated to submembraneous patches or ruffles, and this localization was seen both in the cells expressing WT and Y477F ezrin (Figures 4c and d) . F-actin and ezrin To study the migration and scattering of cells, cell spheroids were seeded on a collagen gel. The morphology of the scattering cells was distinct; the WT ezrin cells showed a rounded morphology (Figure 4g ), whereas the Y477F cells showed an extended morphology. After 14 days, the WT ezrin clone was still growing, whereas the Y477F mutant cells were not vital anymore. Ezrin is a key protein in the amoeboid mode of cancer-cell motility, which involves migration as single cells in a three-dimensional matrix. As earlier publications have implicated a role for Rho kinase in the phenomenon (Sahai and Marshall, 2003) , we treated the WT cells with a Rho kinase inhibitor Y-27632 for comparison. The treated cells stayed longer as a compact spheroid, and the scattering cells showed an extended morphology resembling that of the Y477F mutant cells. If the Src family selective inhibitor PP2 was included in the medium, the spheroids were loose and fragile and the cells could not survive or proliferate. These data imply that the Src-induced phosphorylation of ezrin is specifically involved in the morphology and migration patterns of cells in three-dimensional environments.
We also studied the ability of the subclones to grow in soft agar. The cells expressing WT ezrin but lacking active Src were not able to form colonies in soft agar. The cells containing active Src and the plasmid control formed few colonies, whereas the cells harboring both active Src and WT ezrin formed large and multicellular colonies (Figure 5a ), visible already after 3-4 days. In 2-3 weeks, the number of colonies formed by WT ezrin-expressing cells was fourfold over that of cells expressing active Src alone (Figure 5b) . If the cells expressed Y477F ezrin, growth in soft agar was greatly diminished in comparison with WT ezrin. Moreover, if 
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L Heiska et al the medium in soft agar contained PP2, a selective inhibitor for Src, the growth of the clones coexpressing both WT ezrin and active Src was abolished. The results show that efficient growth of MEF cells in soft agar requires both Src kinase activity and ezrin with an intact Y477 residue. The ability of the subclones to invade three-dimensional matrices was analyzed by counting the cells capable to transverse a layer of Matrigel cast on a porous membrane (Figure 6a ). The presence of the WT but not Y477F ezrin efficiently facilitated the migration of the cells through the matrix in a Src kinase-dependent manner. To analyze the ability of the cells to grow inside a three-dimensional matrix, we quantified the cells growing inside Matrigel after 7 days (Figure 6b ). WT ezrin clones showed increased cell numbers compared with the other subclones. To further study anchorageindependent growth, the subclones were grown in suspension with methyl cellulose (Figure 6c ). Again, coexpression of WT ezrin and active Src promoted cell growth several fold better than Src alone. Furthermore, Y477F ezrin did not provide any growth-promoting effect. The result indicates that the presence of WT ezrin is beneficial in situations of impaired anchorage. Flowcytometric analysis of the cells grown in suspension showed that a significantly higher proportion of WT ezrin-expressing cells were in S þ G2 phase in comparison with Y477F expressing cells.
Previous studies have suggested that ezrin controls mTOR/4E-BP1 pathway (Wan et al., 2005) , with potential effects on cyclin D1 expression. Therefore, we controlled the status of cyclin D1 in cells expressing no ezrin, WT ezrin or Y477F. Immunoblot analysis demonstrated significantly higher cyclin D1 expression in WT ezrin cells when compared with cells lacking ezrin or expressing ezrin Y477F mutant (Figure 6d ). To further evaluate, whether ezrin is regulating the mTOR signaling route, lysates from cells grown in methylcellulose were probed with antibodies recognizing activated signaling intermediates of the Akt/mTOR route. Immunoblot analysis indicated the presence of similar levels of Akt and its phosphorylated form in WT ezrin and Y477F mutant cells. On the other hand, a significant difference in the expression of phosphorylated 4E-BP1 and p70S6K, that is, signaling molecules downstream of mTOR was seen (Figure 6e ). No differences were seen in the levels of phosphorylated p38MAPK or p44/42 MAPK (Erk1/2). The results support a primary role of Src-phosphorylated ezrin in mTOR signaling, at a level downstream of Akt.
To extend the MEF cell studies to epithelial cells, we also characterized the interplay between Src and ezrin in the rat epithelial cell line RK3E, which was transformed by introduction of v-Src (Fu et al., 2005) . Introduction of v-Src induced prominent phosphorylation of several proteins, including ezrin (Figures 7a and b) . Probing with ezrin Y477 phospho-specific antibody confirmed that also this residue was phosphorylated (Figure 7c ). To analyze, whether ezrin Y477 regulates Src-induced malignant features in this model, we transiently expressed WT ezrin and the Y145F and the Y477F In summary, the results indicate that the presence of WT but not Y477F form of ezrin enhances Srcdependent functions that are related to the cell's ability to migrate, invade and proliferate in three-dimensional environment such as mammalian tissue.
Discussion
Oncogenic processes and formation of metastases require complex alterations in cell behavior. Cells must After 14 days, the matrix was fixed, the gel liquefied on ice and the cells were counted. (c) Cells were grown in 0.5% methyl cellulose on bacterial plates. After 7 days, the number of colonies larger than 10 cells were counted by microscopic examination (left panel). (d) After 2 days, cells were analyzed with propidium iodide and flow cytometry and the G1/G2 þ S ratio was calculated (left). The cell lysates were used for western blot analysis of cyclin D1 and tubulin (middle). The signals are expressed as cyclin D1/tubulin ratio (right). The graphs in subfigures a-c are representatives of at least three different experiments with similar results. In d, the bars are mean ± s.d. 5-9 experiments. **Po0.05, ***Po0.01. (e) Cell lysates were probed with antibodies against activated intracellular signaling intermediates.
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L Heiska et al proliferate, overcome contact inhibition, resist apoptotic signals and gain ability to invade. Metastatic processes specifically require the ability to migrate into a new microenvironment and to survive and proliferate outside the tissue of origin. Here, we tested whether ezrin, a multifunctional membrane-cytoskeleton linker, contributes to the oncogenic activity of Src. We used an experimental model of cells lacking endogenous ezrin, which allowed us to contrast the behavior of cells expressing WT ezrin with those lacking ezrin or expressing a mutant version, and to characterize the cellular effects of a single mutated residue. Although ezrin did not participate in the analyzed Src-dependent alterations in two-dimensional cell culture conditions, differences were evident in cells growing in three-dimensional environment or in suspension. In these conditions, ezrin regulates functions related to Src-induced malignancy, and this effect is highly dependent on Y477 residue, a previously characterized Src substrate. Although the literature on Src substrates is extensive, none of its targets have previously been shown to confer advantage specifically in three-dimensional environment. Recently, researchers have increasingly switched to three-dimensional models to understand the cell behavior in vivo. In three-dimensional matrices, cell adhesions are not only formed at the ventral surface, and the matrix both supports physically and provides additional signals for cells. For example, the signaling of small GTPases differs from the signaling in commonly used cell-culture conditions (reviewed in Even-Ram and Yamada, 2005) . In addition, significant differences have been reported in cell motility on planar substrate vs three-dimensional matrix. For studies on tumor cell invasiveness, the three-dimensional models have provided a wealth of novel information.
Several signal transduction networks are connected to ezrin, including the Akt/PI3K cell-survival pathway, which can lead to oncogenesis by disruption of the apoptotic control of cell proliferation. In osteosarcoma metastasis, the Akt/PI3K/mTOR pathways are activated in ezrin-mediated early metastatic survival (Khanna et al., 2004; Wan et al., 2005) . Ezrin has been shown to mediate survival of epithelial cells through the Akt/ PI3K route (Gautreau et al., 1999) , and ezrin knockdown-inhibited Akt phosphorylation in metastatic rhabdomyosarcoma cells (Yu et al., 2006) . Interestingly, ezrin also interacts with hamartin, the gene product of the TSC1 tumor suppressor gene, which is a negative regulator of the mTOR pathway (Lamb et al., 2000) . Src is one of the regulators of PI3K/mTOR signaling networks, providing one possible link to ezrin-mediated malignant behavior. The current results extend the role of ezrin in mTOR signaling, as we noticed an ezrin Y477-dependent difference in the expression of phosphorylated intermediates downstream of mTOR. Thus, ezrin appears to be one of the components that link Src and mTOR. The mTOR pathway regulates translation of cyclin D1 mRNA. The major function of cyclin D1 is to integrate stimuli from extracellular mitogenic factors, such as tyrosine kinases and hormones, with cell-cycle progression during the G1 phase (reviewed in Blain, 2008) . Interestingly, cyclin D1 expression is increased in 
Ezrin regulates Src phenotype in 3D L Heiska et al
Src-transformed fibroblasts and colorectal carcinomas, in which Src is often activated (Sinibaldi et al., 2000; Malek et al., 2002) . Cyclin D1 was upregulated in our suspension cell model suggesting that one mechanism by which Y477-phosphorylated ezrin may provide growth advantage is by regulating cyclin D1.
Ezrin is further participating to Rho family signaling pathways by interacting with Rho GTPase regulating factors and as a target for Rho-dependent threonine phosphorylation (Bretscher et al., 2002) . Intriguingly, ezrin is required for the amoeboid mode of cancer cell invasion in a three-dimensional Matrigel matrix. Inhibition of ezrin or Rho/ROCK signaling blocks the amoeboid motility, whereas proteolytic activity or matrix metalloproteinases are not needed (Sahai and Marshall, 2003) . The localization of ezrin in the cells, which use the amoeboid-type of invasion, is highly concentrated to the direction of the movement, resembling our results with the MEF cells growing inside Matrigel matrix. Moreover, the scattering ezrin WT MEF cells from spheroids on collagen have similar rounded morphology as in the amoeboid motility; here, the inhibition of Rho kinase activity or expression of Y477F-mutated ezrin alter cell morphology from rounded to extended, analogous to a switch from amoeboid to mesenchymal invasion. However, many compensating pathways are exploited when one mechanism of invasion is blocked (Wolf et al., 2003) , and the connections between Rho and Src pathways in threedimensional environment are not known.
According to our results Src appears to have different effects depending on the environment of the cultured cells. As ezrin is not targeting Src, and Src-phosphorylated ezrin has specific binding partners (Heiska and Carpen, 2005; Naba et al., 2008) , it is probable that the metastatic signals mediated by Src rely on dynamic protein interactions of ezrin ultimately leading to malignant behavior. We have been unable to dissect the signaling pathways involved using conventional biochemical studies. As the Src-dependent phosphorylation of ezrin has a role only in three-dimensional culture, we need sensitive tools for detection of differently activated proteins in cells growing in tissue-mimicking conditions. As our MEF cell clones are poorly invasive and do not metastasize in xenograft models, we are currently developing better experimental set-ups to study the effect of Src-induced phosphorylation in a metastatic tumor animal model.
We show that ezrin promotes Src-dependent functions, which are related to the ability to survive anoikis, invade and proliferate in three-dimensional environment, demonstrating one possible mechanism giving selective advantage in tumorigenesis and metastatic processes. As the vast majority of the human deaths in cancer are caused by metastases, most clinical benefit would be obtained by overcoming dissemination and initial steps of metastatic progression. Currently, several Src-kinase inhibitors are in clinical trials (Summy and Gallick, 2006; Kopetz et al., 2007) . However, more research is still needed to identify specific and relevant targets for prevention of metastases.
Materials and methods
Cell lines
Embryonic fibroblasts derived from an ezrin À/À mouse (Saotome et al., 2004) were spontaneously immortalized by serial dilution. Two independently immortalized MEF lines were established and used for generating stable add-back cell lines. All experiments were conducted with the two different sets of cells. For establishing the stable ezrin add-back lines, the WT and the mutant versions of the full-length ezrin complementary DNA were introduced to pBABEpuro vector (Morgenstern and Land, 1990) . The 293 Eco Phoenix retrovirus packaging cell line was transfected with the different constructs, and the virus-containing supernatants were used in the transduction of MEF cells (Miller et al., 1993) . Transfected cells were selected with 2.5 mg/ml of puromycin (SigmaAldrich, St Louis, MO, USA). Constitutively active Src was introduced to the cells with the retroviral construct pLXSHSrcY527F (Cary et al., 2002) , kindly provided by JA Cooper (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). Cells were selected with 0.25 mg/ml of hygromycin B (Calbiochem, La Jolla, CA, USA). The amino-acid numbering of ezrin is according to Krieg and Hunter (1992) . Nontransformed rat epithelial cell line RK3E and its v-Srctransformed subline were a kind gift of S-L Fu (National Yang-Ming University, Taipei, Taiwan) (Fu et al., 2005) .
Antibodies and reagents
Phosphotyrosine was detected with the monoclonal antiphosphotyrosine antibody (mAb) clone PT-66 (SigmaAldrich). Ezrin (Ez9) antibody and ezrin pY477 antibody have been described (Alfthan et al., 2004; Heiska and Carpen, 2005) . Mouse IgG1 (Dako Cytomation, Glostrup, Denmark) or rabbit preimmune serum was used as controls. Phosphospecific antibodies against active (pY418) Src and against phosphorylated (pT558) moesin were from BioSource International (Camarillo, CA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Moesin antibody M22 was a kind gift from Dr Sa Tsukita (Kyoto University, Kyoto, Japan). Mouse Cyclin D1, phospho-p38MAPK, phospho-p44/ 42 MAPK (Erk1/2), phospho-p70S6, phosphor-4EBP1, Akt and phosphor-Akt mAbs were from Cell Signaling Technology (Danvers, MA, USA), and mouse tubulin mAb was from Sigma. Y-27632 (Rho kinase inhibitor) was from Sigma.
Immunoprecipitation of ezrin
The cells were lysed in cold RIPA buffer (50 mm TrisHCl, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM orthovanadate, proatease inhibitor mix, pH 7.4). Ezrin was immunoprecipitated from the supernatants with the Ez9 antibody and protein G Sepharose beads (Amersham Pharmacia, Piscataway, NJ, USA). The sample was analyzed by western blots using appropriate antibodies and ECL detection (Amersham Pharmacia).
Cell proliferation assay Five Â 10 3 cells/well were plated on a 24-well cell-culture plate in quadruple. On the day of analysis, the wells were incubated with 200 ml of 40 mg/ml MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide], Sigma-Aldrich) in phosphate-buffered saline for 3 h, and the converted dye was suspended in 200 ml of dimethyl sulfoxide. Aliquots of 100 ml were analyzed with a microtiter plate reader at 550 nm.
Cell adhesion analysis
The cells were serum-starved overnight, trypsinized and plated at 2 Â 10 5 cells/well in serum-free medium on 96-well cell-culture plates coated with fibronectin (10 mg/ml). The cells were monitored by light microscopy during attachment. At different intervals, the attached cells were stained with crystal violet, and bound dye was measured with a microtiter plate reader at 595 nm after extraction with 0.1% Triton X-100.
Fluorescence microscopy and confocal microscopy Cells were grown on glass coverslips, fixed in 3.5% formaldehyde, permeabilized in 0.1% Triton X-100 in phosphatebuffered saline and incubated sequentially with the antibodies. The secondary antibody was rhodamine-conjugated donkey anti-rabbit or anti-mouse F(ab 0 ) 2 (Jackson Immunoresearch Laboratories, West Grove, PA, USA). F-actin was labelled with rhodamine-conjugated phalloidin (Invitrogen Molecular Probes, Carlsbad, CA, USA). Cells inside Matrigel were stained as described by Debnath et al. (2003) , with slight modifications. Briefly, an eight-well glass chamber slide was first coated with a layer of Matrigel (50 ml/well, BD Biosciences, Franklin Lakes, NJ, USA) and then overlaid with a mixture of 5 Â 10 3 cells, Matrigel (1/3 of the total volume) and culture medium (100 ml). After incubation (24-48 h), the wells were fixed in 3.5% paraformaldehyde, permeabilized in 0.5% Triton X-100 and rinsed with 130 mM NaCl, 7 mM Na 2 HPO 4 , 3.5 mM NaH 2 PO 4 and 100 mM glycine. The wells were blocked in 10% normal swine serum diluted into 130 mM NaCl, 7 mM Na 2 HPO 4 , 3.5 mM NaH 2 PO 4 , 0.1% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween-20, and incubated with the antibodies. The slides were mounted with Mowoil (Calbiochem) mixed 1:3 with 1, 4-diazabicyclo (Sigma-Aldrich) and visualized under epifluorescence microscope or Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany).
Spheroid formation and cell-scattering experiments
The spheroids were formed as described (Eleveld-Trancikova et al., 2002) . Briefly, 5 Â 10 3 cells were made to form spheroids by plating them on U-bottomed microtiter wells, which were precast with a thin film of 1% agar. The cells were incubated for 24-48 h. The formed spheroids were carefully removed and transferred on a 24-well plate, which was precast with a solution containing 1 mg/ml type I collagen (BD Biosciences, Bedford, MA, USA), 10% fetal calf serum and 50 mM NaHCO 3 . The spheroids were overlaid with culture medium and observed by light microscope.
Cell culture in soft agar and in suspension A total of 5 Â 10 4 cells were plated in triplicate in DMEM containing 0.3% agar and 10% fetal calf serum on a layer of precast 0.6% agar. The number and size of the resulting colonies was determined by microscopic visualization after 14-21 days. For growth in suspension, 5 Â 10 5 cells were seeded on bacterial 35 mm plates in a medium containing 0.5% methyl cellulose (Sigma-Aldrich). The clusters of 410 cells from two plates of each subclone were counted under a light microscope after 7-10 days.
Invasion assay
Invasion was measured using growth factor-reduced Matrigel invasion chamber (BD Biosciences) according to the manufacturer's protocol. The inserts were rehydrated with 0.5 ml cell culture medium, 5 Â 10 4 cells were seeded to the chamber in a medium supplemented with 1% fetal calf serum, and the plate wells were filled with 0.75 ml medium supplemented with 10% fetal calf serum. After 36 h, the non-invading cells were removed, the membrane was fixed in 3.5% paraformaldehyde and stained with crystal violet. Invading cells were counted from five different fields using 20 Â magnification.
Cell culture inside Matrigel 96-well microtiter cell-culture plates were precast with 50 ml of Matrigel diluted 1:3 in D-MEM. The layer was overlaid with 100 ml of a mixture containing 5 Â 10 3 cells, Matrigel (1/3 of the volume) and medium. The gel was overlaid with medium and incubated for 14 days. The Matrigel plug was fixed in 100 ml of 3.5% paraformaldehyde, incubated on ice until liquified, and the cells were counted using a hemocytometer.
Flow cytometry
Flow-cytometric analysis was carried out with a FACS Calibur flow cytometer (Beckton-Dickinson, Franklin Lakes, NJ, USA). Cells were fixed in 70% ethanol and dyed with propidium iodide for 30 min at 37 1C in a solution containing 100 mg/ml RNAase A. A total of 10 000 cells per assay were measured.
